YZYuwei Zhang

Yuwei Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuwei Zhang has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Chaohui Yu

    Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    2 shared publications
  • Chenxi Tang

    Department of Gastroenterology, The First Affiliated Hospital, College of Medicine Zhejiang University Hangzhou China

    2 shared publications
  • Jie Zhang

    Department of Gastroenterology, The First Affiliated Hospital, College of Medicine Zhejiang University Hangzhou China

    2 shared publications
  • Jinghua Wang

    Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    2 shared publications
  • Peihao Liu

    Department of Gastroenterology, The First Affiliated Hospital, College of Medicine Zhejiang University Hangzhou China

    2 shared publications
  • Sha Li

    Department of Gastroenterology, The First Affiliated Hospital, College of Medicine Zhejiang University Hangzhou China

    2 shared publications

Latest Publications

  • Exploration of a Potential Amoxicillin MIC Threshold in Bismuth Quadruple Therapy for H. pylori Infection in Southeastern China

    by Ding Lu, Zhen‐Wei Yang, Yun‐Fan Dong, Yu‐Wei Zhang, Jiang Liu

    Objective: The European Committee on Antimicrobial Susceptibility Testing (EUCAST) defines the amoxicillin resistance breakpoint at a minimum inhibitory concentration (MIC) of 0.125 μg/mL. This breakpoint is widely applied, and its clinical relevance has been validated in regions where amoxicillin‐based triple therapy is the standard. However, in the context of China's predominant use of quadruple therapy, the applicability of this breakpoint remains unclear. This study aimed to collect Southeastern China resistance data, assess the impact of different amoxicillin MIC thresholds on the efficacy of amoxicillin‐containing quadruple therapy, and to explore candidate amoxicillin MIC thresholds potentially associated with treatment outcomes. Methods: Gastric mucosal specimens were obtained from patients undergoing gastroscopy between March 2024 and March 2025. A total of 4203 Helicobacter pylori isolates were successfully cultured and included for in vitro susceptibility testing. In vitro susceptibility testing of H. pylori isolates was performed using the agar dilution method, with MIC thresholds for amoxicillin set at 0.125 μg/mL, 0.25 μg/mL, 0.5 μg/mL, 1 μg/mL, and 2 μg/mL and other antibiotics (clarithromycin, metronidazole, levofloxacin) was performed on H. pylori isolates via agar dilution method. Patients treated with an amoxicillin‐containing quadruple regimen (rabeprazole 10 mg twice daily + bismuth potassium citrate 220 mg twice daily + amoxicillin 1.0 g twice daily + furazolidone 100 mg twice daily or tetracycline 100 mg twice daily) were followed up. Eradication status was assessed by 13 C‐urea breath test 6–8 weeks post‐treatment. Eradication rates were calculated using both intention‐to‐treat (ITT) and per‐protocol (PP) analyses. χ 2 test with Yates' continuity correlation and Fisher's exact tests were applied for group comparisons. Kappa statistics were used to evaluate the level of agreement between resistance classification under different MIC thresholds and clinical eradication outcomes. Prespecified stratified analyses were performed, and interaction terms were included in regression models to examine whether the association between amoxicillin MIC and eradication outcomes was consistent across treatment regimens and clinical subgroups. Results: A total of 342 patients were included in the ITT analysis, and 330 patients were included in the PP analysis after excluding 14 patients due to adverse events or loss to follow‐up. When the MIC breakpoint was set at 0.125 μg/mL or 0.25 μg/mL, no statistically significant difference was observed between resistant and susceptible groups in eradication rates (0.125 μg/mL: resistant ITT 88.57%, PP 90.29% vs. susceptible ITT 91.56%, PP 95.59%; 0.25 μg/mL: resistant ITT 86.89%, PP 88.33% vs. susceptible ITT 91.46%, PP 95.19%; all p > 0.05). At 0.5 μg/mL, eradication rates in resistant patients were significantly lower (ITT 77.42%, PP 80.00%) than those in susceptible patients (ITT 91.96%, PP 95.33%) ( p < 0.05). At 1 μg/mL, eradication in resistant patients was 66.67% (ITT) and 72.73% (PP), significantly lower than susceptible patients (ITT 91.52%, PP 94.67%) ( p < 0.05). The highest kappa coefficient (0.180) was observed at the 0.5 μg/mL threshold, indicating the strongest—albeit slight—agreement between resistance classification and treatment outcome. Conclusion: In patients receiving bismuth‐containing quadruple therapy, an amoxicillin MIC threshold of 0.5 μg/mL appears to better reflect clinically relevant resistance than the EUCAST‐defined breakpoint of 0.125 μg/mL. This threshold may serve as a more suitable candidate breakpoint for guiding empirical BQT in this region, although validation in larger, multicenter prospective studies is required.

  • The DEAD ‐box helicase DDX3x ameliorates non‐alcoholic fatty liver disease via mTORC1 signalling pathway

    by Peihao Liu, Yuwei Zhang, Chenxi Tang, Li Cen, Yishu Chen, Sha Li, Xueyang Chen, Mengli Yu, Jie Zhang, Xiaofen Zhang, et al.

    Background & Aims: The DEAD (Asp‐Glu‐Ala‐Asp)‐box helicase family member DDX3x has been proven to involve in hepatic lipid disruption during HCV infection. However, the role of DDX3x in non‐alcoholic fatty liver disease (NAFLD), in which lipid homeostasis is severely disrupted, remains unclear. Here, we aimed to illustrate the potential role of DDX3x in NAFLD. Methods: DDX3x protein levels were evaluated in NAFLD patients and NAFLD models via immunohistochemistry or western blotting. In vivo ubiquitin assay was performed to identify the ubiquitination levels of DDX3x in the progression of steatosis. DDX3x protein levels in mice livers were manipulated by adeno‐associated virus‐containing DDX3x short hairpin RNA or DDX3x overexpression plasmid. Hepatic or serum triglyceride and total cholesterol were evaluated and hepatic steatosis was confirmed by haematoxylin and eosin staining and oil red o staining. Western blotting was performed to identify the underlying mechanisms of DDX3x involving in the progression of NAFLD. Results: DDX3x protein levels were significantly decreased in NAFLD patients and NAFLD models. DDX3x protein might be degraded via ubiquitin–proteasome system in the progression of steatosis. Knockdown of hepatic DDX3x exacerbated HFD‐induced hepatic steatosis in mice, while overexpression of hepatic DDX3x alleviated HFD‐induced hepatic steatosis in mice. Further explorative experiments revealed that knockdown of DDX3x could lead to the overactivation of mTORC1 signalling pathway which exacerbates NAFLD. Conclusions: DDX3x involved in the progression of NAFLD via affecting the mTORC1 signalling pathway. DDX3x might be a potential target for NAFLD treatment.


  • GCSF deficiency attenuates nonalcoholic fatty liver disease through regulating GCSFR-SOCS3-JAK-STAT3 pathway and immune cells infiltration

    by Yuwei Zhang, Xuefeng Zhou, Peihao Liu, Xueyang Chen, Jie Zhang, Hong Zhang, Sha Li, Yishu Chen, Xin Song, Jinghua Wang, et al.

    Granulocyte colony stimulating factor (GCSF) is a cytokine with immunomodulation effects. However, little is known about its role in metabolic diseases. In the current study, we aimed to explore the role of GCSF in nonalcoholic fatty liver disease (NAFLD). Male GCSF−/− mice were used to investigate the function of GCSF in vivo after high-fat diet (HFD). Primary hepatocytes were used for evaluating the function of GCSF in vitro. Liver immune cells were isolated and analyzed by flow cytometry. Our results showed that GCSF administration significantly increased serum triglyceride (TG) levels in patients. Circulating GCSF was markedly elevated in HFD-fed mice. GCSF−/− mice exhibited alleviated HFD-induced obesity, insulin resistance, and hepatic steatosis. Extra administration of GCSF significantly aggravated palmitic acid (PA)-induced lipid accumulation in primary hepatocytes. Mechanically, GCSF could bind to granulocyte colony stimulating factor receptor (GCSFR) and regulate suppressors of cytokine signaling 3, Janus kinase, signal transducer and activator of transcription 3 (SOCS3-JAK-STAT3) pathway. GCSF also enhanced hepatic neutrophils and macrophages infiltration, thereby modulating NAFLD. These findings suggest that GCSF plays an important regulatory role in NAFLD and may be a potential therapeutic target for NAFLD. NEW & NOTEWORTHY We found GCSF was involved in lipid metabolism and NAFLD development. GCSF administration increased serum triglyceride levels in patients. GCSF deficiency alleviated HFD-induced insulin resistance and hepatic steatosis in mice. GCSF could directly act on hepatocytes through GCSFR-SOCS3-JAK-STAT3 pathway, and regulate the infiltration of immune cells into the liver to indirectly modulate NAFLD. Our finding indicates that GCSF may provide new strategies for the treatment of NAFLD.


  • Open Access

    Berberine attenuates mitochondrial dysfunction by inducing autophagic flux in myocardial hypoxia/reoxygenation injury

    by Na Zhu, Xueming Cao, Peiyuan Hao, Yuwei Zhang, Yan Chen, Jing Zhang, Jiang Li, Chuanyu Gao, Li Li


  • Inhibition of Histone Deacetylation by MS-275 Alleviates Colitis by Activating the Vitamin D Receptor

    by Chunxiao Li, Yi Chen, Huatuo Zhu, Xiuming Zhang, Lu Han, Zuodong Zhao, Jinghua Wang, Longgui Ning, Weihua Zhou, Chao Lu, et al.

    Background: Ulcerative colitis [UC] is a common chronic inflammatory bowel disease without curative treatment. Methods: We conducted gene set enrichment analysis to explore potential therapeutic agents for UC. Human colon tissue samples were collected to test H3 acetylation in UC. Both in vivo and in vitro colitis models were constructed to verify the role and mechanism of H3 acetylation modification in UC. Intestine-specific vitamin D receptor [VDR]-/- mice and VD [vitamin D]-deficient diet-fed mice were used to explore downstream molecular mechanisms accordingly. Results: According to the Connectivity Map database, MS-275 [class I histone deacetylase inhibitor] was the top-ranked agent, indicating the potential importance of histone acetylation in the pathogenesis of UC. We then found that histone H3 acetylation was significantly lower in the colon epithelium of UC patients and negatively associated with disease severity. MS-275 treatment inhibited histone H3 deacetylation, subsequently attenuating nuclear factor kappa B [NF-κB]-induced inflammation, reducing cellular apoptosis, maintaining epithelial barrier function, and thereby reducing colitis activity in a mouse model of colitis. We also identified VDR as be a downstream effector of MS-275. The curative effect of MS-275 on colitis was abolished in VDR-/- mice and in VD-deficient diet-fed mice and VDR directly targeted p65. In UC patients, histone H3 acetylation, VDR and zonulin-1 expression showed similar downregulation patterns and were negatively associated with disease severity. Conclusions: We demonstrate that MS-275 inhibits histone deacetylation and alleviates colitis by ameliorating inflammation, reducing apoptosis, and maintaining intestinal epithelial barrier via VDR, providing new strategies for UC treatment.


  • Missense mutation in PRKCQ is associated with Crohn's disease

    by Yu Wei Zhang, Xiao Ying Xu, Jie Zhang, Xin Yao, Chao Lu, Chun Xiao Chen, Chao Hui Yu, Jing Sun

    Objective: Recent genome‐wide association studies have demonstrated that rs2236379 in PRKCQ is a novel significant locus for Crohn's disease (CD). However, the association has not been replicated in any populations. We therefore aimed to investigate the prevalence of the PRKCQ rs2236379 variant in the Chinese Han population and evaluate whether the genetic variant of PRKCQ confers susceptibility to CD and is associated with its clinical characteristics.Methods: A total of 283 patients with CD and 381 healthy controls were enrolled. Genomic DNA was extracted from their whole blood samples and polymerase chain reaction‐restriction fragment length polymorphism was used for genotyping. The association between PRKCQ polymorphisms and susceptibility to CD, and between genotypes and clinical phenotypes was analyzed.Results: A higher frequency of the T allele was discovered in CD patients than in healthy controls (P = 0.027). A significant difference in the distribution of the TT and CT/CC genotypes was observed between CD patients and controls (P = 0.024). The TT genotype showed a significant association with susceptibility to CD (odds ratio 1.647, 95% confidence interval: 1.088‐2.574, P = 0.019). Patients with CD with the rs2236379 TT mutant risk genotype were most likely to exhibit perianal disease (P = 0.044).Conclusions: Our research revealed an association between the PRKCQ rs2236379 (C>T) and CD. The TT homozygous mutation increased the risk of developing CD and may contribute to perianal disease.